ELCC 2025 – J&J takes it to Tagrisso
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
ALX plays the conjugate card
Could a new ADC project distract attention away from evorpacept?
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Avenzo follows Bristol’s lead
The private group taps DualityBio for an EGFR x HER3 ADC.
